(NASDAQ:ALT) NEW YORK, Sept. 1, 2025 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead...
Related Questions
How might the potential lawsuit settlement or judgment affect ALT's stock price and volatility in the short term?
What are the estimated financial exposures (e.g., potential damages or settlement costs) and could they impact ALT's balance sheet or cash flow?
How does this securities fraud claim compare to similar recent litigation against biotech peers, and what precedent might it set for future investor lawsuits?